Salzhauer Michael increased its position in Cerus Corporation (NASDAQ:CERS) by 16.0% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 363,019 shares of the biotechnology company’s stock after buying an additional 50,000 shares during the period. Salzhauer Michael owned approximately 0.35% of Cerus Corporation worth $912,000 at the end of the most recent quarter.
A number of other institutional investors also recently added to or reduced their stakes in the company. Teachers Advisors LLC boosted its position in Cerus Corporation by 0.4% in the fourth quarter. Teachers Advisors LLC now owns 269,964 shares of the biotechnology company’s stock worth $1,174,000 after buying an additional 1,152 shares in the last quarter. Stephens Inc. AR boosted its position in shares of Cerus Corporation by 0.3% in the first quarter. Stephens Inc. AR now owns 950,729 shares of the biotechnology company’s stock valued at $4,231,000 after buying an additional 2,539 shares during the period. American International Group Inc. boosted its position in shares of Cerus Corporation by 7.1% in the first quarter. American International Group Inc. now owns 62,374 shares of the biotechnology company’s stock valued at $278,000 after buying an additional 4,127 shares during the period. Metropolitan Life Insurance Co. NY boosted its position in shares of Cerus Corporation by 7.9% in the first quarter. Metropolitan Life Insurance Co. NY now owns 81,132 shares of the biotechnology company’s stock valued at $361,000 after buying an additional 5,920 shares during the period. Finally, Marathon Capital Management boosted its position in shares of Cerus Corporation by 32.4% in the first quarter. Marathon Capital Management now owns 24,500 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 6,000 shares during the period. Institutional investors and hedge funds own 65.09% of the company’s stock.
Cerus Corporation (NASDAQ CERS) traded up 2.05% during midday trading on Friday, hitting $2.49. 536,449 shares of the stock were exchanged. Cerus Corporation has a 1-year low of $1.93 and a 1-year high of $7.19. The stock’s market cap is $271.75 million. The company’s 50 day moving average is $2.36 and its 200-day moving average is $3.36.
Cerus Corporation (NASDAQ:CERS) last posted its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16). The firm had revenue of $9.53 million for the quarter, compared to the consensus estimate of $9.14 million. Cerus Corporation had a negative net margin of 164.39% and a negative return on equity of 120.31%. The business’s revenue was up 3.0% compared to the same quarter last year. During the same period last year, the firm posted ($0.18) earnings per share. On average, analysts expect that Cerus Corporation will post ($0.68) earnings per share for the current year.
WARNING: This story was first posted by BNB Daily and is the sole property of of BNB Daily. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/13/salzhauer-michael-has-912000-position-in-cerus-corporation-nasdaqcers-updated-updated-updated.html.
Several equities analysts have issued reports on the stock. BidaskClub upgraded shares of Cerus Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Zacks Investment Research upgraded shares of Cerus Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, June 27th. ValuEngine cut shares of Cerus Corporation from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 17th. Cantor Fitzgerald restated a “buy” rating and issued a $7.00 price target on shares of Cerus Corporation in a research report on Wednesday, June 7th. Finally, BTIG Research restated a “buy” rating and issued a $5.00 price target on shares of Cerus Corporation in a research report on Sunday, May 28th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. Cerus Corporation presently has a consensus rating of “Hold” and an average target price of $7.25.
About Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related companies with MarketBeat.com's FREE daily email newsletter.